Strep Viridans Bacteremia: Causes, Symptoms, and Treatment

Viridans group streptococci (VGS) are bacteria that normally live harmlessly in your mouth, gut, and urinary tract, but when they cross into the bloodstream they can cause a serious infection called bacteremia. In healthy people this rarely happens, but in those with weakened immune systems, damaged heart valves, or disrupted mucosal barriers, VGS bacteremia can lead to life-threatening complications including septic shock, respiratory failure, and infective endocarditis. Understanding how these ordinarily mild organisms become dangerous, who faces the greatest risk, and how clinicians diagnose and treat the infection matters because VGS bacteremia is both common and surprisingly variable in severity.

What the Viridans Group Actually Is

The name “viridans” comes from the Latin word for “green,” referring to the greenish halo these bacteria produce on blood agar plates (alpha-hemolysis). But “viridans group streptococci” is not a single species. It is a large, loosely defined collection of species organized into several subgroups, including the mitis group, the mutans group, the salivarius group, the bovis group, and the anginosus group. Each behaves somewhat differently in terms of where it colonizes, how it resists antibiotics, and what kind of disease it tends to cause.

The mitis group, which includes Streptococcus mitis and Streptococcus oralis, is the subgroup most frequently isolated from blood cultures in patients with cancer and low white blood cell counts. The anginosus group (S. anginosus, S. constellatus, S. intermedius) tends to form deep-seated abscesses, and delayed diagnosis of anginosus bacteremia is associated with increased illness and death.¹ Species like S. gordonii, S. sanguinis, and S. mutans are strongly linked to infective endocarditis. This diversity is one reason VGS bacteremia is not one-size-fits-all: the species involved shapes both the clinical picture and the urgency of the workup.

How the Bacteria Get Into the Bloodstream

Because VGS colonize the mouth, gastrointestinal tract, and genitourinary tract, any disruption to those mucosal surfaces can open a door into the blood.² The most studied route is the oral one. Dental procedures like tooth extraction create obvious portals of entry. In one study, about two-thirds of patients had positive blood cultures after a tooth extraction, and the rate was significantly higher in patients who also had periodontitis (roughly 79%) compared with those who did not (about 57%). The bacterial strains recovered from the blood matched those found in the patients’ subgingival plaque, confirming the mouth as the source.³

But you do not need a dental procedure to push these organisms into your blood. Even everyday activities like tooth brushing and flossing can cause transient bacteremia. A study in Circulation concluded that because people brush their teeth far more often than they visit the dentist, the cumulative exposure from routine oral hygiene may pose a greater bacteremia risk to vulnerable individuals than an occasional extraction.⁴ Dental flossing produces bacteremia at rates comparable to some dental treatments for which antibiotic prophylaxis is recommended.⁵

In cancer patients, the route is often different. Chemotherapy drugs damage the lining of the mouth and gut, a condition called mucositis, which strips away the barrier that normally keeps oral and intestinal bacteria contained. A real-world study of patients with blood cancers found that mucosal barrier injury was an independent risk factor for bloodstream infection, with viridans group streptococci among the predominant organisms isolated in these cases.⁶

Who Is Most at Risk

The single biggest risk factor is neutropenia, the severe drop in infection-fighting white blood cells that follows intensive chemotherapy or stem cell transplantation. In a case-control study comparing neutropenic and non-neutropenic patients with VGS bacteremia, the depth of the neutropenia itself was the strongest predictor of infection among neutropenic patients. Interestingly, recent vancomycin use appeared to be protective against VGS bacteremia in that group.⁷ In children with fever and neutropenia, high-dose cytarabine chemotherapy stood out as a strong independent predictor of VGS bacteremia.⁸

Outside of cancer care, people with pre-existing heart valve disease, prosthetic heart valves, or a history of endocarditis face elevated risk because VGS have a particular affinity for damaged cardiac tissue. Intravenous drug use, poor dentition, and immunosuppressive therapy for organ transplant or autoimmune conditions also raise the likelihood that transient bacteremia will become persistent and dangerous.

Symptoms and Clinical Presentation

VGS bacteremia can present across a wide spectrum. At the mild end, a patient develops a fever and feels generally unwell while blood cultures turn positive; the infection clears with antibiotics and causes no lasting harm. At the severe end, the picture is dramatically different. A review in the American Journal of Medicine reported that VGS bacteremia in neutropenic patients can be accompanied by acute respiratory distress syndrome (ARDS) in roughly 3% to 33% of cases, shock in 7% to 18%, and endocarditis in 7% to 8%.⁹

The most feared acute complication is viridans streptococcal shock syndrome (VSSS). An early landmark study found that about a quarter of patients with VGS septicemia developed a shock syndrome marked by dangerously low blood pressure, a skin rash, peeling palms, respiratory failure, and sometimes death.¹⁰ Streptococcus mitis is the species implicated in most cases of this syndrome.¹¹ During bone marrow transplantation, VSSS can be rapidly fatal. One report described five patients who developed bilateral lung infiltrates, respiratory failure, and septic shock within the first week after transplant; all five died.¹²

Less commonly, VGS bacteremia can trigger neurological problems. A case series documented encephalopathy, including seizures and loss of consciousness, in pediatric cancer patients with VGS bloodstream infections. Those who developed encephalopathy tended to have markedly higher inflammatory markers than those who did not.¹³

The Infective Endocarditis Connection

VGS remain a leading cause of infective endocarditis, a condition where bacteria colonize the heart valves and form clumps called vegetations. Several VGS species are adept at sticking to heart tissue. Laboratory research has shown that species like S. gordonii attach to human endothelial cells through hair-like surface structures and then invade the cells using specific surface proteins, including glucosyltransferase and a sialic acid-binding protein called Hsa.¹⁴ Similarly, S. sanguinis relies on virulence factors encoded by specific genes to form cardiac vegetations; when those genes are knocked out in animal models, the bacteria fail to establish endocarditis.¹⁵

Because the risk of endocarditis varies by species, clinical guidelines now risk-stratify patients based on which VGS is isolated. A proposed algorithm separates streptococci into four tiers. Species like S. gordonii, S. gallolyticus, S. mutans, and S. sanguinis are classified as very high risk and warrant both transthoracic and transesophageal echocardiography regardless of other factors. At the other end, species like S. pneumoniae and S. pyogenes are low risk and generally do not need initial imaging unless multiple blood culture bottles are positive and the patient has additional risk factors.¹⁶ Species in the mitis/oralis group fall into a high-risk tier where echocardiography is recommended whenever risk factors or multiple positive bottles are present.

Notably, in neutropenic cancer patients, endocarditis from VGS is uncommon even when bacteremia occurs. A retrospective study of neutropenic patients with gram-positive bacteremia found only a single case of infective endocarditis among the cohort, and even in that case the echocardiogram failed to demonstrate valvular pathology.¹⁷ This has led some clinicians to question whether routine echocardiography in every neutropenic patient with VGS bacteremia is necessary, though the decision depends heavily on the clinical picture.

Diagnosing VGS Bacteremia

Blood cultures remain the cornerstone of diagnosis. When VGS grow in a blood culture bottle, the lab faces two practical challenges: figuring out which species it is, and deciding whether it represents a true infection or a contaminant from the skin or collection process.

Species identification has improved with mass spectrometry technology (MALDI-TOF MS), which can identify bacteria within minutes by analyzing their protein fingerprint. However, VGS are notoriously difficult to tell apart. Studies comparing MALDI-TOF instruments with gene sequencing have found that while modern systems reliably distinguish VGS from the closely related Streptococcus pneumoniae, they still struggle with certain species within the mitis and bovis groups.¹⁸ In-house database refinements can push species-level accuracy above 95%, compared with about 79% for some commercially available systems.¹⁹ Gene sequencing remains the gold standard when precise species-level identification is needed, particularly for guiding the endocarditis risk-stratification mentioned above.²⁰

The contamination question is trickier. VGS live on skin and mucosal surfaces, so a single positive blood culture bottle can represent true bacteremia or simply bacteria that snuck into the bottle during the blood draw. Time to positivity, meaning how quickly bacteria grow in the culture bottle, offers a useful clue. A large study found that the median time to positivity was about 19 hours for true VGS bacteremia versus roughly 26 hours for contamination. A cutoff of 20 hours offered a reasonable balance between sensitivity and specificity.²¹ In practice, clinicians weigh the time to positivity alongside the number of positive bottles, the patient’s clinical state, and whether the species identified carries a high endocarditis risk.

Treatment and Antibiotic Choices

For VGS bacteremia caused by susceptible strains, intravenous penicillin G or ampicillin has long been the standard treatment, particularly for endocarditis cases. But penicillin is inconvenient: it requires continuous or frequent infusion throughout the day. A study comparing ceftriaxone (which can be given once daily) with penicillin G in patients with complicated VGS bacteremia found no significant difference in outcomes. Ceftriaxone-treated patients had a composite adverse event rate of about 14%, versus 27% with penicillin, a difference that did not reach statistical significance but at least suggests ceftriaxone is a reasonable alternative.²² The convenience of once-daily dosing makes ceftriaxone attractive for outpatient parenteral antibiotic therapy, which lets patients complete long courses of treatment at home.

Vancomycin is reserved for patients allergic to beta-lactam antibiotics or when resistance is a concern. For endocarditis specifically, treatment guidelines often recommend combining a cell-wall-active agent like penicillin or ceftriaxone with an aminoglycoside for the initial phase, depending on the species and its susceptibility profile.

Rising Antibiotic Resistance

The assumption that VGS are universally sensitive to penicillin no longer holds. The mitis group species, particularly S. mitis and S. oralis, are frequently nonsusceptible to penicillin.²³ In one study of VGS blood culture isolates from patients with underlying diseases, about 30% were resistant to penicillin and 36% were resistant to erythromycin.²⁴ A 10-year pediatric review similarly found that 30% of VGS isolates in children undergoing cancer treatment or stem cell transplant were penicillin-resistant, though all remained susceptible to vancomycin.²⁵

The mechanism behind this resistance is a fascinating example of bacteria sharing genetic material. Penicillin-resistant VGS have acquired altered penicillin-binding protein genes from Streptococcus pneumoniae through horizontal gene transfer. Researchers found that the resistance genes in S. sanguis and S. oralis were essentially copied from the mosaic gene variants found in penicillin-resistant pneumococci.²⁶ This gene swapping may be accelerated in patients who have received repeated courses of antibiotics, creating a selection pressure that favors resistant strains. The practical consequence is that susceptibility testing on VGS blood isolates is not optional; clinicians cannot assume penicillin will work.

Endocarditis Prophylaxis

The American Heart Association (AHA) has maintained a consistent position on preventing VGS endocarditis since 2007. Antibiotic prophylaxis before dental procedures is recommended only for the highest-risk patients: those with prosthetic heart valves, a history of endocarditis, certain congenital heart defects, or cardiac transplants with valve problems. The AHA reaffirmed this stance in a 2021 scientific statement, noting that no new evidence justified expanding prophylaxis to additional patient groups.²⁷

The statement also emphasized that maintaining good oral health and regular dental care is at least as important as taking a single dose of antibiotics before a procedure. Given that daily brushing and flossing produce their own episodes of bacteremia, having healthy gums may do more long-term good than any prophylactic antibiotic regimen.

VGS Bacteremia in Children

Pediatric cancer patients are a group where VGS bacteremia is especially concerning. Children receiving intensive chemotherapy for leukemia, neuroblastoma, and other malignancies develop severe mucositis that allows oral bacteria to flood into the bloodstream. In a study of pediatric oncology patients, VGS accounted for a quarter of all positive blood cultures, making it the single most commonly isolated pathogen. Children with high-risk neuroblastoma during induction chemotherapy had VGS bacteremia rates roughly three times higher than children with acute lymphoblastic leukemia and seven times higher than those with other solid tumors.²⁸

The shock syndrome is not only an adult problem. In the 10-year pediatric review mentioned earlier, about 15% of VGS bacteremia episodes in children resulted in viridans streptococcal shock syndrome. Six of those eight episodes required intensive care, and three of the children died of multiorgan failure.²⁵ These numbers underscore that VGS bacteremia in pediatric oncology is not a nuisance infection to be managed casually.

Prognosis and What Predicts Poor Outcomes

Overall mortality from VGS bacteremia varies widely depending on the patient’s underlying condition and how quickly complications develop. A study examining outcomes found a three-month mortality rate of about 22% among patients with VGS bacteremia. Independent predictors of death included low blood pressure at the onset of bacteremia, prior use of steroids or immunosuppressive therapy, and a high burden of other medical conditions.²⁹ In other words, the sicker you were before the bacteremia hit, the worse your odds. Early recognition, rapid blood cultures, prompt initiation of appropriate antibiotics, and targeted cardiac imaging based on the species involved give patients the best chance of avoiding the most dangerous complications.

Why Species-Level Identification Matters More Than It Used To

A recurring theme in VGS bacteremia research is that lumping all viridans streptococci together obscures clinically important differences. The endocarditis risk from S. gordonii or S. sanguinis is substantially higher than from S. salivarius. The shock syndrome risk is concentrated in S. mitis. Abscess formation is characteristic of the anginosus group. Penicillin resistance is most common in the mitis group. Each of these distinctions changes the workup and treatment plan. Yet many older clinical studies, and some hospital microbiology labs today, report results simply as “viridans streptococci” without further differentiation. As mass spectrometry platforms improve their VGS databases and gene sequencing becomes more accessible, the expectation is increasingly that species-level identification should be pursued, especially when blood cultures are positive in a high-risk patient. That granularity can mean the difference between a reassuring observation period and an urgent echocardiogram.